Xencor (XNCR) Aandelenoverzicht
Xencor, Inc., een biofarmaceutisch bedrijf in een klinische fase, richt zich op het ontdekken en ontwikkelen van gemanipuleerde antilichamen voor de behandeling van kanker en auto-immuunziekten. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 5/6 |
| Dividenden | 0/6 |
XNCR Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Xencor, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$11.31 |
| 52 Week Hoogtepunt | US$18.69 |
| 52 Week Laag | US$6.92 |
| Bèta | 0.93 |
| 1 maand verandering | -12.87% |
| 3 maanden verandering | -4.23% |
| 1 Jaar Verandering | 49.41% |
| 3 jaar verandering | -58.50% |
| 5 jaar verandering | -70.59% |
| Verandering sinds IPO | 35.61% |
Recent nieuws en updates
Analyseartikel • May 11
These Analysts Just Made A Huge Downgrade To Their Xencor, Inc. (NASDAQ:XNCR) EPS Forecasts
One thing we could say about the analysts on Xencor, Inc. ( NASDAQ:XNCR ) - they aren't optimistic, having just made a...
Narratiefupdate • May 02
XNCR: Refined Q4 Assumptions And Regulatory Shifts Will Drive Future Repricing
Analysts have kept Xencor's fair value estimate steady at $43.00, while modestly adjusting assumptions for discount rate, revenue growth, profit margin, and future P/E after recent research. This research includes a $1 price target increase to $27 from $26.00, alongside a downgrade based on expectations for fewer near term catalysts.
Narratiefupdate • Apr 18
XNCR: Mixed Catalyst Outlook And Regulatory Shifts Will Shape Future Repricing
Analysts have increased their price target on Xencor by $1 to $27, citing updated models after the Q4 report, even as some see limited near term catalysts to significantly change the story. Analyst Commentary Recent research on Xencor reflects a more cautious tone, with some high profile firms highlighting limited catalysts and execution risk, even as models are refreshed following the Q4 report.Narratiefupdate • Apr 03
XNCR: T Cell Engagers And Mixed Catalyst Outlook Will Shape Multi Year Repricing
Narrative Update The analyst fair value estimate for Xencor has been reset from $18.00 to $13.00 as analysts factor in a lack of near term, needle moving catalysts highlighted in recent research, along with updated models following the Q4 report and sector wide reassessments of U.S. biopharmaceutical valuations. Analyst Commentary Recent Street research on Xencor reflects a mix of views, and the reset in fair value has been driven mainly by more cautious commentary around the near term outlook and the timing of impactful catalysts.Recent updates
Analyseartikel • May 11
These Analysts Just Made A Huge Downgrade To Their Xencor, Inc. (NASDAQ:XNCR) EPS Forecasts
One thing we could say about the analysts on Xencor, Inc. ( NASDAQ:XNCR ) - they aren't optimistic, having just made a...Narratiefupdate • May 02
XNCR: Refined Q4 Assumptions And Regulatory Shifts Will Drive Future Repricing
Analysts have kept Xencor's fair value estimate steady at $43.00, while modestly adjusting assumptions for discount rate, revenue growth, profit margin, and future P/E after recent research. This research includes a $1 price target increase to $27 from $26.00, alongside a downgrade based on expectations for fewer near term catalysts.Narratiefupdate • Apr 18
XNCR: Mixed Catalyst Outlook And Regulatory Shifts Will Shape Future Repricing
Analysts have increased their price target on Xencor by $1 to $27, citing updated models after the Q4 report, even as some see limited near term catalysts to significantly change the story. Analyst Commentary Recent research on Xencor reflects a more cautious tone, with some high profile firms highlighting limited catalysts and execution risk, even as models are refreshed following the Q4 report.Narratiefupdate • Apr 03
XNCR: T Cell Engagers And Mixed Catalyst Outlook Will Shape Multi Year Repricing
Narrative Update The analyst fair value estimate for Xencor has been reset from $18.00 to $13.00 as analysts factor in a lack of near term, needle moving catalysts highlighted in recent research, along with updated models following the Q4 report and sector wide reassessments of U.S. biopharmaceutical valuations. Analyst Commentary Recent Street research on Xencor reflects a mix of views, and the reset in fair value has been driven mainly by more cautious commentary around the near term outlook and the timing of impactful catalysts.Narratiefupdate • Mar 20
XNCR: Sector Tailwinds And T Cell Engagers Will Drive Multi Year Repricing
Analysts have nudged their Xencor models after recent sector-wide updates and the latest Q4 report, with Street price targets moving into a roughly $20 to $27 range. The internal fair value anchor in this framework holds near $18, reflecting tempered revenue and margin assumptions offset by supportive biopharma sentiment.Narratiefupdate • Mar 06
XNCR: Reset Pipeline Milestones And Sector Tailwinds Will Drive Repricing
Analysts have raised their Xencor fair value estimate from $40.00 to $43.00, reflecting refreshed models and higher Street price targets, including recent moves to $27 and $20, supported by updated company assumptions and broader biotech sector drivers cited in recent research. Analyst Commentary Recent Street research on Xencor points to a more constructive stance on the stock, with bullish analysts revisiting their models after the latest quarterly update and broader sector checks.Narratiefupdate • Feb 20
XNCR: T Cell Engagers In Solid Tumors Will Drive Multi Year Repricing
Analysts raised their Xencor price target to $20 from $17, citing an improving environment for U.S. biotech funding and deal activity, as well as greater market recognition of recent positive data catalysts. Analyst Commentary Recent commentary around Xencor frames the higher US$20 price target within a broader reassessment of U.S. biopharmaceutical names.Analyseartikel • Feb 13
Xencor, Inc. (NASDAQ:XNCR) Shares Could Be 28% Below Their Intrinsic Value Estimate
Key Insights Xencor's estimated fair value is US$16.09 based on 2 Stage Free Cash Flow to Equity Xencor's US$11.62...
Narratiefupdate • Feb 06
XNCR: Constructive Biopharma Backdrop Will Support Future Oncology Upside
Narrative Update Analysts have nudged their 12 month price target for Xencor higher from US$17 to US$20, citing a more constructive backdrop for U.S. biopharmaceuticals, improving access to capital, supportive M&A activity, and recent positive data catalysts now being reflected in valuations. Analyst Commentary Recent commentary around Xencor centers on how it fits into a broader recovery in U.S. biopharmaceuticals, with the new US$20 price target reflecting both improved sector conditions and ongoing uncertainty about how durable these supports will be.Narratiefupdate • Jan 23
XNCR: T Cell Engagers And TL1A Pipeline Will Drive Multi Year Repricing
Analysts have nudged their price targets on Xencor higher to a range of US$20 to US$42, pointing to positive recent data readouts, a more constructive view on the T cell engager and TL1A pipeline, and a generally more supportive biotech funding backdrop. Analyst Commentary Recent Street research on Xencor clusters around a more constructive view of its T cell engager and TL1A programs, but opinions are not uniformly bullish.Narratiefupdate • Jan 08
XNCR: T Cell Engager Pipeline Progress Will Drive Multi Year Repricing Potential
Narrative Update Analysts have lifted their Xencor fair value estimate from US$8.67 to US$18.00. This change reflects higher Street price targets in the US$20 to US$42 range and growing confidence in the company's T cell engager pipeline following recent data updates and conference presentations.Seeking Alpha • Jan 01
Xencor: Fortress Balance Sheet Bodes Well For XmAb819 And XmAb942
Summary XNCR pairs a wholly owned antibody pipeline with XmAb platform partnerships. This way, they get milestones, licensing revenue, and royalties. This approach lets them partially fund their internal R&D. But on top of that, XNCR has ample liquid resources it can tap into as needed. XNCR’s lead immunology asset XmAb942 is in Phase 2b for ulcerative colitis. And this candidate could help validate their ability to advance late-stage assets internally. Management also believes that RCC spending is concentrated in a few branded therapies. This could prove an interesting opportunity for their platform. Thus, I feel XNCR offers compelling upside potential with its drug candidates for long-term investors, despite its inherent early-stage and partner risks. Read the full article on Seeking AlphaNarratiefupdate • Dec 18
XNCR: Advancing T Cell Engagers Will Drive Future Oncology Upside
We are nudging our Xencor fair value estimate slightly higher to $28.25 from $28.00, reflecting analysts' increased price targets and improved sentiment around the company's T cell engager and TL1A antibody programs following encouraging early stage data and clearer late stage development visibility. Analyst Commentary Recent Street research reflects a constructive but still risk balanced view on Xencor, with multiple firms lifting price targets as they factor in stronger T cell engager data and growing conviction in the TL1A program, while still highlighting execution and clinical readout risks that could impact long term value realization.Narratiefupdate • Dec 04
XNCR: Advancing T Cell Engager Pipeline Will Drive Future Upside Potential
Xencor's analyst price target has inched higher to about $28.00 from roughly $27.91, as analysts factor in stronger long term value from the company's advancing T cell engager and TL1A antibody programs, despite modest tweaks to growth and margin assumptions. Analyst Commentary Recent Street research reflects a generally improving stance on Xencor, with several bullish analysts lifting price targets as confidence grows in the company’s T cell engager and TL1A programs, while more cautious voices continue to emphasize execution and clinical risk.Analyseartikel • Nov 25
There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 27% Share Price Rise
Xencor, Inc. ( NASDAQ:XNCR ) shares have continued their recent momentum with a 27% gain in the last month alone...Narratiefupdate • Nov 20
XNCR: Advancing Late-Stage Antibody Programs Will Drive Upside Into 2025
The analyst price target for Xencor edged higher to $27.91 from $27.64 after analysts cited improved revenue growth outlook and progress across key clinical programs. Analyst Commentary Recent Street research on Xencor reflects a range of views, with several analysts updating their models and outlooks following new data from clinical programs and company updates.Narratiefupdate • Nov 05
XNCR: Positive Early Oncology Data Will Accelerate Future Upside Potential
Xencor's analyst price target has increased from $25.73 to $27.64, with analysts citing positive pipeline updates and an improved outlook on novel oncology programs as drivers of the higher valuation. Analyst Commentary Analyst sentiment on Xencor has shifted notably in recent months, reflecting emerging data from clinical studies and evolving perspectives on the company's future growth potential.Narratiefupdate • Oct 22
Analysts Weigh Xencor Pipeline Progress as Price Targets Inch Higher on Positive Data
The analyst price target for Xencor has increased modestly, rising by $0.18 per share as analysts cite encouraging initial data for its XmAb819 therapy and a slightly improved outlook on pipeline progress, despite ongoing development challenges. Analyst Commentary Recent Street research provides a mixed outlook on Xencor, reflecting both optimism around its emerging therapies and caution due to the company's ongoing development challenges and market execution risks.Narratiefupdate • Oct 08
IBD Biologics And TL1A Programs Will Forge New Paths
Analysts have raised their price target for Xencor from $24.10 to $25.55 per share. This reflects moderate optimism despite concerns around limited near-term catalysts and extended development timelines described in recent research commentary.Analyseartikel • Sep 25
There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 31% Share Price Rise
Xencor, Inc. ( NASDAQ:XNCR ) shareholders have had their patience rewarded with a 31% share price jump in the last...Analyseartikel • Sep 18
Health Check: How Prudently Does Xencor (NASDAQ:XNCR) Use Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Narratiefupdate • Aug 22
IBD Biologics And TL1A Programs Will Forge New Paths
Analysts have reduced their price target for Xencor to $25.20 amid optimism for key pipeline assets but tempered by concerns over limited data, lack of near-term catalysts, and execution speed. Analyst Commentary Stock price seen as undervaluing Xencor's three main business pillars: IBD franchise led by '942, immunology efforts led by plamotamab, and the oncology bispecific platform.Analyseartikel • Aug 06
Xencor, Inc.'s (NASDAQ:XNCR) Price Is Right But Growth Is Lacking
NasdaqGM:XNCR 1 Year Share Price vs Fair Value Explore Xencor's Fair Values from the Community and select yours With a...Nieuw narratief • Jul 06
IBD Biologics And TL1A Programs Will Forge New Paths
Differentiated drug design and flexible development platform position Xencor for increased patient adoption, operational efficiency, and attractive long-term profitability.Analyseartikel • Apr 26
Is Xencor (NASDAQ:XNCR) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Mar 30
Xencor, Inc. (NASDAQ:XNCR) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely
To the annoyance of some shareholders, Xencor, Inc. ( NASDAQ:XNCR ) shares are down a considerable 27% in the last...Analyseartikel • Feb 04
Some Confidence Is Lacking In Xencor, Inc. (NASDAQ:XNCR) As Shares Slide 27%
Xencor, Inc. ( NASDAQ:XNCR ) shares have had a horrible month, losing 27% after a relatively good period beforehand...Seeking Alpha • Jan 30
Xencor: Substantial Promise, Slow Progress
Summary Today, I revisit Xencor, Inc., a developmental biotech concern for the first time since 2017. The company is advancing a diverse pipeline that consists of both licensed and wholly owned candidates. Xencor has a strong cash position, projecting $707 million in cash and marketable securities by year-end, bolstered by a recent $200 million secondary offering. Xencor's pipeline has some significant promise, but progress has been notably slow over the years. An updated analysis around Xencor follows in the paragraphs below. Read the full article on Seeking AlphaAnalyseartikel • Dec 31
Is Xencor (NASDAQ:XNCR) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyseartikel • Dec 03
Xencor, Inc.'s (NASDAQ:XNCR) 26% Share Price Surge Not Quite Adding Up
Despite an already strong run, Xencor, Inc. ( NASDAQ:XNCR ) shares have been powering on, with a gain of 26% in the...Analyseartikel • Nov 10
Xencor, Inc. (NASDAQ:XNCR) Just Reported And Analysts Have Been Cutting Their Estimates
Shareholders of Xencor, Inc. ( NASDAQ:XNCR ) will be pleased this week, given that the stock price is up 11% to...Seeking Alpha • Sep 12
Xencor: Vudalimab Development Along With Hidden Gem Candidate
Summary Monotherapy and combination dose cohort data from the phase 2 study, using vudalimab for the treatment of patients with mCRPC, expected 1st half of 2025. The global metastatic castrate-resistant prostate cancer treatment market size is projected to reach $20.70 billion by 2031. XmAb942 is a candidate in the company's pipeline which has the potential to become the best in class anti-TL1A inhibitor for the treatment of autoimmune disorders like UC and CD. The global market for inflammatory bowel disease is expected to cross $30 billion by 2031. Read the full article on Seeking AlphaAnalyseartikel • Sep 12
Xencor, Inc.'s (NASDAQ:XNCR) 34% Share Price Surge Not Quite Adding Up
Xencor, Inc. ( NASDAQ:XNCR ) shareholders are no doubt pleased to see that the share price has bounced 34% in the last...Analyseartikel • Sep 06
Calculating The Fair Value Of Xencor, Inc. (NASDAQ:XNCR)
Key Insights The projected fair value for Xencor is US$16.92 based on 2 Stage Free Cash Flow to Equity With US$16.32...Analyseartikel • Jul 13
Does Xencor (NASDAQ:XNCR) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyseartikel • Jun 16
Lacklustre Performance Is Driving Xencor, Inc.'s (NASDAQ:XNCR) Low P/S
You may think that with a price-to-sales (or "P/S") ratio of 7.8x Xencor, Inc. ( NASDAQ:XNCR ) is a stock worth...Analyseartikel • Mar 27
Is Xencor (NASDAQ:XNCR) Weighed On By Its Debt Load?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Feb 27
There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 29% Share Price Rise
Despite an already strong run, Xencor, Inc. ( NASDAQ:XNCR ) shares have been powering on, with a gain of 29% in the...Seeking Alpha • Feb 03
Xencor: Standing Out With XmAb Technology
Summary Xencor demonstrates strong YoY revenue growth through achieved milestones with major industry partners. The strategic sale of royalty interests strengthens Xencor's balance sheet and provides flexibility for future strategic moves. Xencor's pipeline developments and clinical trials show a focus on promising therapies in oncology and autoimmune diseases. Read the full article on Seeking AlphaAnalyseartikel • Jan 05
Xencor, Inc.'s (NASDAQ:XNCR) Business And Shares Still Trailing The Industry
You may think that with a price-to-sales (or "P/S") ratio of 9.3x Xencor, Inc. ( NASDAQ:XNCR ) is a stock worth...Analyseartikel • Nov 13
Xencor, Inc. (NASDAQ:XNCR) Analysts Just Cut Their EPS Forecasts Substantially
One thing we could say about the analysts on Xencor, Inc. ( NASDAQ:XNCR ) - they aren't optimistic, having just made a...Analyseartikel • Nov 10
Companies Like Xencor (NASDAQ:XNCR) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Analyseartikel • Aug 08
Party Time: Brokers Just Made Major Increases To Their Xencor, Inc. (NASDAQ:XNCR) Earnings Forecasts
Shareholders in Xencor, Inc. ( NASDAQ:XNCR ) may be thrilled to learn that the analysts have just delivered a major...Rendement voor aandeelhouders
| XNCR | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 2.3% | 2.4% | 1.1% |
| 1Y | 49.4% | 34.6% | 28.7% |
Rendement versus industrie: XNCR overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 34.6 % opleverde.
Rendement versus markt: XNCR overtrof de US markt, die het afgelopen jaar een rendement opleverde van 28.7 %.
Prijsvolatiliteit
| XNCR volatility | |
|---|---|
| XNCR Average Weekly Movement | 9.6% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: XNCR heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 10% ) van XNCR is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1997 | 260 | Bassil Dahiyat | www.xencor.com |
Xencor, Inc., een biofarmaceutisch bedrijf in een klinische fase, richt zich op het ontdekken en ontwikkelen van gemanipuleerde antilichamen voor de behandeling van kanker en auto-immuunziekten. Het bedrijf levert Ultomiris voor de behandeling van patiënten met atypisch hemolytisch uremisch syndroom, gegeneraliseerde myasthenia gravis en neuromyelitis optica spectrum stoornis; en Monjuvi voor de behandeling van patiënten met recidief of refractair diffuus groot B-cel lymfoom. Het ontwikkelt ook XmAb819, een bispecifiek antilichaam voor de behandeling van niercelcarcinoom; XmAb541, dat zich in Fase I bevindt voor de behandeling van eierstokkanker; XmAb808, een bispecifiek antilichaam dat zich bindt aan het breed uitgedrukte tumorantigeen; XmAb942, dat zich in klinische ontwikkeling bevindt voor patiënten met de ziekte van Crohn en colitis ulcerosa; Plamotamab, een bispecifiek T-cel, dat zich in Fase Ib bevindt voor de behandeling van reumatoïde artritis; en XmAb657 voor patiënten met idiopathische inflammatoire myopathieën.
Xencor, Inc. Samenvatting
| XNCR fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$838.54m |
| Inkomsten(TTM) | -US$172.42m |
| Inkomsten(TTM) | US$97.36m |
8.6x
P/S-verhouding-4.9x
Koers/WinstverhoudingIs XNCR overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| XNCR resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$97.36m |
| Kosten van inkomsten | US$245.53m |
| Brutowinst | -US$148.16m |
| Overige uitgaven | US$24.26m |
| Inkomsten | -US$172.42m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -2.33 |
| Brutomarge | -152.18% |
| Nettowinstmarge | -177.10% |
| Schuld/Eigen Vermogen Verhouding | 21.0% |
Hoe presteerde XNCR op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/25 02:39 |
| Aandelenkoers aan het einde van de dag | 2026/05/22 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Xencor, Inc. wordt gevolgd door 24 analisten. 13 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Peter Lawson | Barclays |
| Etzer Darout | Barclays |
| Zhiqiang Shu | Berenberg |